Cargando…

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) affect immunologic homeostasis, leading to immune-related adverse events (irAEs). Early irAE detection and management can prevent significant morbidity and mortality. A retrospective chart review was performed to characterize irAEs associated with nivolumab, ipili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teimouri, Arezou, Minard, Laura V., Scott, Samantha N., Daniels, Amanda, Snow, Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139722/ https://www.ncbi.nlm.nih.gov/pubmed/35621642 http://dx.doi.org/10.3390/curroncol29050252

Ejemplares similares

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population
por: van Beek, Michiel W. H., et al.
Publicado: (2018)

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
por: Zhai, Yinghong, et al.
Publicado: (2019)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world
por: Nishida, Toshirou, et al.
Publicado: (2019)

Walk Your Talk: Real-World Adherence to Guidelines on the Use of MRI in Multiple Sclerosis
por: Tortora, Mario, et al.
Publicado: (2021)

Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions
por: Lavon, Ophir, et al.
Publicado: (2019)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
por: Armstrong, Ehrin J., et al.
Publicado: (2014)

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
por: Shimozaki, Keitaro, et al.
Publicado: (2020)

Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022
por: Wu, Si, et al.
Publicado: (2022)

Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence
por: Shepard, Colin W., et al.
Publicado: (2002)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda
por: Davies, Emma C., et al.
Publicado: (2012)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

A quality improvement project reducing adverse events and improving adherence to guidelines surrounding VRIII usage
por: Coulden, Amy, et al.
Publicado: (2022)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
por: Jain, P., et al.
Publicado: (2021)

Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2016)

THU281 Real-World Survey Of Adherence To Guidelines Regarding Type 1 Diabetes And Aerobic Exercise
por: Anthony Henske, Joseph, et al.
Publicado: (2023)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
por: Cottini, Francesca, et al.
Publicado: (2021)

Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
por: Engel-Nitz, Nicole M., et al.
Publicado: (2020)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
por: Shi, Yuequan, et al.
Publicado: (2021)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Stroke prevention and guideline adherent antithrombotic treatment in elderly patients with atrial fibrillation: A real-world experience
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia
por: Ali, Salma R, et al.
Publicado: (2020)

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
por: Umetsu, Ryogo, et al.
Publicado: (2021)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database
por: Liu, Yunwei, et al.
Publicado: (2022)

Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
por: Ge, Xiaoxiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r0ig1h7prckabmr21b2k9o5u7c